vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and OLAPLEX HOLDINGS, INC. (OLPX). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $105.1M, roughly 1.6× OLAPLEX HOLDINGS, INC.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 4.3%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 3.1%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Olaplex Holdings, Inc. is a specialty beauty company developing and selling patented bond-repair hair care products. It runs three core segments: professional salon distribution, direct-to-consumer sales, and third-party retail, serving customers across North America, Europe, and Asia-Pacific with products that repair and protect damaged hair.
ESPR vs OLPX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $105.1M |
| Net Profit | — | $-13.1M |
| Gross Margin | — | 68.0% |
| Operating Margin | 50.6% | -4.3% |
| Net Margin | — | -12.5% |
| Revenue YoY | 143.7% | 4.3% |
| Net Profit YoY | — | -48.9% |
| EPS (diluted) | $0.32 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $105.1M | ||
| Q3 25 | $87.3M | $114.6M | ||
| Q2 25 | $82.4M | $106.3M | ||
| Q1 25 | $65.0M | $97.0M | ||
| Q4 24 | $69.1M | $100.7M | ||
| Q3 24 | $51.6M | $119.1M | ||
| Q2 24 | $73.8M | $103.9M | ||
| Q1 24 | $137.7M | $98.9M |
| Q4 25 | — | $-13.1M | ||
| Q3 25 | $-31.3M | $11.1M | ||
| Q2 25 | $-12.7M | $-7.7M | ||
| Q1 25 | $-40.5M | $465.0K | ||
| Q4 24 | — | $-8.8M | ||
| Q3 24 | $-29.5M | $14.8M | ||
| Q2 24 | $-61.9M | $5.8M | ||
| Q1 24 | $61.0M | $7.7M |
| Q4 25 | — | 68.0% | ||
| Q3 25 | — | 69.1% | ||
| Q2 25 | — | 71.2% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.3% | ||
| Q3 24 | — | 68.6% | ||
| Q2 24 | — | 69.7% | ||
| Q1 24 | — | 72.1% |
| Q4 25 | 50.6% | -4.3% | ||
| Q3 25 | -11.4% | 3.7% | ||
| Q2 25 | 8.6% | -1.1% | ||
| Q1 25 | -34.0% | 8.7% | ||
| Q4 24 | -6.4% | 3.0% | ||
| Q3 24 | -31.0% | 23.5% | ||
| Q2 24 | 3.5% | 15.7% | ||
| Q1 24 | 52.5% | 19.8% |
| Q4 25 | — | -12.5% | ||
| Q3 25 | -35.9% | 9.7% | ||
| Q2 25 | -15.4% | -7.3% | ||
| Q1 25 | -62.2% | 0.5% | ||
| Q4 24 | — | -8.7% | ||
| Q3 24 | -57.2% | 12.4% | ||
| Q2 24 | -83.9% | 5.6% | ||
| Q1 24 | 44.3% | 7.8% |
| Q4 25 | $0.32 | $-0.02 | ||
| Q3 25 | $-0.16 | $0.02 | ||
| Q2 25 | $-0.06 | $-0.01 | ||
| Q1 25 | $-0.21 | $0.00 | ||
| Q4 24 | $-0.14 | $-0.01 | ||
| Q3 24 | $-0.15 | $0.02 | ||
| Q2 24 | $-0.33 | $0.01 | ||
| Q1 24 | $0.34 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $318.7M |
| Total DebtLower is stronger | — | $352.3M |
| Stockholders' EquityBook value | $-302.0M | $879.4M |
| Total Assets | $465.9M | $1.5B |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $318.7M | ||
| Q3 25 | $92.4M | $286.4M | ||
| Q2 25 | $86.1M | $289.3M | ||
| Q1 25 | $114.6M | $580.9M | ||
| Q4 24 | $144.8M | $586.0M | ||
| Q3 24 | $144.7M | $538.8M | ||
| Q2 24 | $189.3M | $507.9M | ||
| Q1 24 | $226.6M | $507.5M |
| Q4 25 | — | $352.3M | ||
| Q3 25 | — | $352.1M | ||
| Q2 25 | — | $351.9M | ||
| Q1 25 | — | $649.1M | ||
| Q4 24 | — | $650.5M | ||
| Q3 24 | — | $651.8M | ||
| Q2 24 | — | $653.1M | ||
| Q1 24 | — | $654.4M |
| Q4 25 | $-302.0M | $879.4M | ||
| Q3 25 | $-451.4M | $888.7M | ||
| Q2 25 | $-433.5M | $874.2M | ||
| Q1 25 | $-426.2M | $878.3M | ||
| Q4 24 | $-388.7M | $874.4M | ||
| Q3 24 | $-370.2M | $879.7M | ||
| Q2 24 | $-344.2M | $863.3M | ||
| Q1 24 | $-294.3M | $855.7M |
| Q4 25 | $465.9M | $1.5B | ||
| Q3 25 | $364.0M | $1.5B | ||
| Q2 25 | $347.1M | $1.5B | ||
| Q1 25 | $324.0M | $1.8B | ||
| Q4 24 | $343.8M | $1.8B | ||
| Q3 24 | $314.1M | $1.8B | ||
| Q2 24 | $352.3M | $1.8B | ||
| Q1 24 | $373.1M | $1.8B |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.40× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.74× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.76× | ||
| Q1 24 | — | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $32.7M |
| Free Cash FlowOCF − Capex | — | $32.6M |
| FCF MarginFCF / Revenue | — | 31.0% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $58.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $32.7M | ||
| Q3 25 | $-4.3M | $8.0M | ||
| Q2 25 | $-31.4M | $20.9M | ||
| Q1 25 | $-22.6M | $-2.9M | ||
| Q4 24 | $-35.0M | $49.7M | ||
| Q3 24 | $-35.3M | $33.5M | ||
| Q2 24 | $-7.2M | $16.2M | ||
| Q1 24 | $53.8M | $43.7M |
| Q4 25 | — | $32.6M | ||
| Q3 25 | — | $7.9M | ||
| Q2 25 | — | $20.8M | ||
| Q1 25 | — | $-3.0M | ||
| Q4 24 | — | $49.2M | ||
| Q3 24 | $-35.5M | $33.3M | ||
| Q2 24 | $-7.3M | $16.1M | ||
| Q1 24 | $53.8M | $43.3M |
| Q4 25 | — | 31.0% | ||
| Q3 25 | — | 6.9% | ||
| Q2 25 | — | 19.6% | ||
| Q1 25 | — | -3.1% | ||
| Q4 24 | — | 48.9% | ||
| Q3 24 | -68.7% | 28.0% | ||
| Q2 24 | -9.9% | 15.5% | ||
| Q1 24 | 39.0% | 43.7% |
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.1% | 0.1% | ||
| Q1 24 | 0.1% | 0.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.72× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -6.27× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.26× | ||
| Q2 24 | — | 2.81× | ||
| Q1 24 | 0.88× | 5.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
OLPX
| Sales Channel Directly To Consumer | $43.6M | 42% |
| Sales Channel Through Intermediary Professional | $36.8M | 35% |
| Sales Channel Through Intermediary Specialty Retail | $24.7M | 23% |
